Wave Life Sciences

Wave Life Sciences is a biotechnology company with a powerful vision to transform human health by unlocking the broad potential of RNA medicines. The company's RNA medicines platform, PRISM, integrates various modalities, chemistry innovation, and deep insights into human genetics to bring about scientific breakthroughs addressing both rare and prevalent disorders. This platform includes RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, providing the company with unparalleled capabilities to design and deliver candidates that effectively tackle disease biology. Wave Life Sciences has a diverse pipeline of clinical programs focusing on Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington’s disease, and a preclinical program in obesity. The company's commitment to "Reimagine Possible" is reflected in its dedication to adapting human potential free from the burden of disease. Founded in 2012, the company operates primarily in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. Its most recent milestone was a significant Post-IPO Equity investment on 24 September 2024, which signifies continued confidence in the company's potential for positive impact on human health.